These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 20477976

  • 1. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
    Lapidus-Krol E, Shapiro R, Amir J, Davidovits M, Steinberg R, Mor E, Avitzur Y.
    Pediatr Transplant; 2010 Sep 01; 14(6):753-60. PubMed ID: 20477976
    [Abstract] [Full Text] [Related]

  • 2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 3. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF.
    Biol Blood Marrow Transplant; 2009 Jun 15; 15(6):730-40. PubMed ID: 19450758
    [Abstract] [Full Text] [Related]

  • 4. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 15; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 5. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
    Bedel AN, Hemmelgarn TS, Kohli R.
    Liver Transpl; 2012 Mar 15; 18(3):347-54. PubMed ID: 22139888
    [Abstract] [Full Text] [Related]

  • 6. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L, Rabella N, Díaz JM, Facundo C, Maderuelo A, Margall N, Silva I, García-Maset R, Calabia J, Giménez I, Garra N, Solà R, Ballarín JA.
    Nefrologia; 2008 Mar 15; 28(3):293-300. PubMed ID: 18590496
    [Abstract] [Full Text] [Related]

  • 7. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 15; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

  • 8. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A, RESITRA.
    Clin Infect Dis; 2008 Jan 01; 46(1):20-7. PubMed ID: 18171208
    [Abstract] [Full Text] [Related]

  • 9. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 01; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 01; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 11. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O, Berkovitch M, Rom E, Bilavsky E, Bernfeld Y, Dorfman L, Pappo A, Ziv-Baran T, Brandriss N, Bar-Haim A, Amir J, Ashkenazi-Hoffnung L.
    Pediatr Infect Dis J; 2017 Aug 01; 36(8):745-750. PubMed ID: 28383392
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.
    Pharmacotherapy; 2004 Oct 01; 24(10):1323-30. PubMed ID: 15628830
    [Abstract] [Full Text] [Related]

  • 13. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC.
    Antivir Ther; 2005 Oct 01; 10(1):119-23. PubMed ID: 15751769
    [Abstract] [Full Text] [Related]

  • 14. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.
    Transplantation; 2007 Feb 15; 83(3):290-6. PubMed ID: 17297403
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA.
    Transplantation; 2015 Jul 15; 99(7):1499-505. PubMed ID: 25643140
    [Abstract] [Full Text] [Related]

  • 16. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 15; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 17. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec 15; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
    Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, Aigner C, Klepetko W.
    J Heart Lung Transplant; 2009 Jul 15; 28(7):670-5. PubMed ID: 19560694
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R.
    Transplant Proc; 2004 Dec 15; 36(10):3107-12. PubMed ID: 15686707
    [Abstract] [Full Text] [Related]

  • 20. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May 15; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.